Astrazeneca Pharma India Ltd.

8,423.5

174 (2.1%)stock indicator image for upward trend

As on June 15, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap20,581 Cr
P/E Ratio178.19
Dividend Yield0.19 %
Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

This image for unlock stock of the monthUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open8,260
High8,461
NSE SymbolASTRAZEN
Close8,423.5
Low8,234.5
BSE Symbol506820
Previous Years High/Low
1 Year High10,559
3 Year High10,691
5 Year High10,691
1 Year Low7,551.5
3 Year Low3,575
5 Year Low2,445.7

Technicals


IndicatorsValueSignal
5-DMA8,328.6Bullish
10-DMA8,436.8Bearish
20-DMA8,556.73Bearish
50-DMA8,414.35Bullish
100-DMA8,498.23Bearish
200-DMA8,752.69Bearish

Historical Performance


1 Year
-19.8%
3 Years
130.7%
5 Years
121.2%
10 Years
710.4%

Shareholding Pattern


%

Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


Compounded Sales Growth
10 Years:27.1
5 Years:15.6
3 Years:16.3
TTM:5.8
Compounded Profit Growth
10 Years:14
5 Years:9.9
3 Years:13.4
TTM:-6.4
Stock Price CAGR
10 Years:22.9
5 Years:17.4
3 Years:32.2
TTM:-18
Return on Equity
10 Years:2.1
5 Years:37.3
3 Years:39.7
last year:46.3

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a high PE of 178.19, indicating expensive valuation or elevated growth expectations.
  • Over the last three years, the stock delivered a strong 3-year price CAGR of 31.2%, indicating sustained price appreciation.
  • The stock carries a low beta of 0.4, suggesting lower volatility than the broader market.
  • In the last financial year, the company reported an EBITDA of ₹2946 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹17163 million, indicating a large and established business.

Investment Calculator


Investment Amount: ₹ 1000000
Current Value: ₹ 820524.1
No. of Shares: 97 (Approx)
Performance:-17.9%
P/L: ₹-179475.9
NIFTY Performance: -4.4%
1 day Top Gainers
SymbolChange%
AARTIIND498.15(13%)
KALYANKJIL383(11%)
SCHNEIDER1216.2(10%)
BALKRISIND2192.5(9%)
SUNDARMFIN4466.9(7%)
1 Day Top Losers
SymbolChange%
RELINFRA81.55(-5%)
AUROPHARMA1408.3(-4%)
ZEEL108.49(-4%)
OLAELEC44.12(-4%)
ASTERDM786.7(-4%)
DEEPAKFERT1508.3(-3%)
GVT&D4805.5(-3%)
TEJASNET582.35(-3%)

Top Performing Stocks from the same sector


Venus Remedies Ltd.

106.5%

1883

1 Month Performance

Bliss GVS Pharma Ltd.

58.3%

439.55

1 Month Performance

Brooks Laboratories Ltd.

44.9%

67.55

1 Month Performance

Beta Drugs Ltd.

44.3%

1835.6

1 Month Performance

Sun Pharma Advanced Research Company Ltd.

40%

229.03

1 Month Performance

Rubicon Research Ltd.

39.9%

1344.4

1 Month Performance

Panacea Biotec Ltd.

39.9%

540.8

1 Month Performance

Supriya Lifescience Ltd.

38.7%

955.2

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month